Ipsogen, a cancer profiler that markets molecular diagnostic assays for leukemia and breast cancer, has launched the MapQuant Dx HER2 test in Europe.


Developed on the MapQuant Dx microarray diagnostic platform, MapQuant Dx HER2 accurately measures a set of HER2-amplified genes that correlate with HER2 protein expression, the company said. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients, the company added.

Jean-Marc Le Doussal, director of the breast cancer program at Ipsogen, said: "MapQuant Dx HER2 is the second test to be developed on our MapQuant Dx platform, after the Genomic Grade launched by Ipsogen earlier in 2008. Thanks to our experience in molecular diagnostics and to multiple research collaborations, we will keep delivering innovative tests at an accelerated pace."

Francois Bertucci, medical oncologist at Institut Paoli Calmettes Cancer Center in Marseille, said: "I was very pleased to collaborate with Ipsogen in rapidly and efficiently moving from our research findings to a market-ready diagnostic test. As a translational researcher, I believe that MapQuant Dx is a comprehensive 'plug and play' solution, making research rapidly available to patients."